Meanwhile, LPA can also increase fibroblast growth factor-23 (FGF23) in acute and chronic kidney injury levels to promote chronic fibrosis, which is closely associated with subsequent CKD and end-stage renal disease (11). Here, FGF23 is linked to stage 5 chronic kidney disease.